Literature DB >> 32922063

IL-6 -572C>G and CARD8 304T>A Genetic Polymorphisms are Associated with the Absolute Neutrophil Count in Patients with Hematological Malignancies Under Chemotherapy: An Application of Multilevel Models to a Preliminary Pharmacogenetic Study.

Matias F Martinez1,2, Enzo Alveal1, Tomas G Soto1,3, Eva I Bustamante4, Fernanda Ávila5, Shrikant I Bangdiwala6,7, Ivonne Flores4, Claudia Benavides4, Ricardo Morales4, Nelson M Varela1,2, Luis A Quiñones1,2.   

Abstract

PURPOSE: Neutropenia is a common event in patients undergoing cytotoxic chemotherapy for the treatment of a hematological malignancy. Some polymorphisms, as IL-6 -572C>G (rs1800796), IL-1β -31 G>A (rs1143627), and CARD8 304T>A (rs2043211), in genes related to the inflammatory process, could affect the level of absolute neutrophil count (ANC) after chemotherapy. Since an efficient inflammatory process enhances neutrophil survival, we hypothesize that these polymorphisms are associated with ANC. PATIENTS AND METHODS: We carried out a prospective cohort study in two hospitals in Santiago, Chile. The patients included were adults diagnosed with acute myeloblastic leukemia, acute lymphoblastic leukemia, or non-Hodgkin's lymphoma, undergoing cytotoxic chemotherapy. We use a multilevel linear regression model to test our hypothesis. The best model was selected using the Akaike's information criterion (AIC).
RESULTS: We analyzed 1726 hemograms and ANCs from 172 hospitalizations from 32 patients. The results show that CC and CG genotypes of IL-6 -572 C>G polymorphism are associated with higher ANCs compared with the GG genotype (Ln (ANC) ~ 0.81 IC95% 0.02-1.55). Similarly, TT and AT genotypes of CARD8 304T>A polymorphism were related to higher ANCs compared with AA (Ln (ANC) ~ 0.95 IC95% 0.02-1.82). IL-1β genetic polymorphism had no statistically significant association with ANC.
CONCLUSION: IL-6 rs1800796 -572C>G and CARD8 rs2043211 304T>A polymorphisms are associated with the absolute neutrophil count in patients undergoing cytotoxic chemotherapy for treatment of hematological malignancies. Our findings might be useful to improve the safety of chemotherapy through predictive ANC models.
© 2020 Martinez et al.

Entities:  

Keywords:  CARD8 protein; hematological neoplasms; interleukin-6; leukemia; lymphoma; neutropenia; pharmacogenetics

Year:  2020        PMID: 32922063      PMCID: PMC7450656          DOI: 10.2147/PGPM.S261208

Source DB:  PubMed          Journal:  Pharmgenomics Pers Med        ISSN: 1178-7066


  24 in total

1.  Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130.

Authors:  Andrew N Wilkinson; Kate H Gartlan; Greg Kelly; Luke D Samson; Stuart D Olver; Judy Avery; Nienke Zomerdijk; Siok-Keen Tey; Jason S Lee; Slavica Vuckovic; Geoffrey R Hill
Journal:  J Immunol       Date:  2018-04-06       Impact factor: 5.422

2.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

Review 3.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

4.  Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

Authors:  J Klastersky; J de Naurois; K Rolston; B Rapoport; G Maschmeyer; M Aapro; J Herrstedt
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

5.  Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.

Authors:  Randy A Taplitz; Erin B Kennedy; Eric J Bow; Jennie Crews; Charise Gleason; Douglas K Hawley; Amelia A Langston; Loretta J Nastoupil; Michelle Rajotte; Kenneth Rolston; Lynne Strasfeld; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2018-02-20       Impact factor: 44.544

6.  Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Authors:  Heinz Ludwig; Carsten Bokemeyer; Matti Aapro; Mario Boccadoro; Pere Gascón; Kris Denhaerynck; Andriy Krendyukov; Ivo Abraham; Karen MacDonald
Journal:  Future Oncol       Date:  2019-03-04       Impact factor: 3.404

7.  A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.

Authors:  Elio Castagnola; Vincenzo Fontana; Ilaria Caviglia; Silvia Caruso; Maura Faraci; Francesca Fioredda; Maria Luisa Garrè; Cristina Moroni; Massimo Conte; Giuseppe Losurdo; Franca Scuderi; Roberto Bandettini; Paolo Tomà; Claudio Viscoli; Riccardo Haupt
Journal:  Clin Infect Dis       Date:  2007-10-05       Impact factor: 9.079

8.  Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.

Authors:  Sebnem Yilmaz; Hale Oren; Fatih Demircioğlu; Gülersu Irken
Journal:  Pediatr Hematol Oncol       Date:  2008 Apr-May       Impact factor: 1.969

9.  Impact of interleukin 6 promoter polymorphisms (-174 G > C, -572 G > C and -597 G > A) on plasma IL-6 levels and their influence on the development of DVT: a study from India.

Authors:  Amit Sharma; Kanwaljeet Singh; Arijit Biswas; Ravi Ranjan; Kamal Kishor; Hareram Pandey; Ravi Kumar; Manoranjan Mahapatra; Johannes Oldenburg; Renu Saxena
Journal:  Hematology       Date:  2018-06-11       Impact factor: 2.269

Review 10.  Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis.

Authors:  Dinesh Vyas; Gieric Laput; Arpitak K Vyas
Journal:  Onco Targets Ther       Date:  2014-06-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.